Published in Virology on June 05, 2002
Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol (2004) 1.93
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol (2004) 1.71
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol (2007) 1.22
Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J Virol (2003) 0.98
De novo initiation pocket mutations have multiple effects on hepatitis C virus RNA-dependent RNA polymerase activities. J Virol (2004) 0.93
Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J Virol (2005) 0.90
Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob Agents Chemother (2008) 0.90
Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. J Virol (2012) 0.86
Residues Arg283, Arg285, and Ile287 in the nucleotide binding pocket of bovine viral diarrhea virus NS5B RNA polymerase affect catalysis and fidelity. J Virol (2012) 0.82
Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. PLoS One (2014) 0.81
Identification of a structural element of the hepatitis C virus minus strand RNA involved in the initiation of RNA synthesis. Nucleic Acids Res (2010) 0.80
Hydrophobic and charged residues in the C-terminal arm of hepatitis C virus RNA-dependent RNA polymerase regulate initiation and elongation. J Virol (2014) 0.78
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Needlescopic lung biopsy for interstitial lung disease and indeterminate pulmonary nodules: a report on 65 cases. Ann Thorac Surg (2008) 1.43
Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Proc Natl Acad Sci U S A (2013) 1.42
A plant-specific calreticulin is a key retention factor for a defective brassinosteroid receptor in the endoplasmic reticulum. Proc Natl Acad Sci U S A (2009) 1.40
The role of OsBRI1 and its homologous genes, OsBRL1 and OsBRL3, in rice. Plant Physiol (2006) 1.32
Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett (2007) 1.30
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 1.23
Conserved endoplasmic reticulum-associated degradation system to eliminate mutated receptor-like kinases in Arabidopsis. Proc Natl Acad Sci U S A (2010) 1.22
In vitro RNA replication directed by replicase complexes isolated from the subgenomic replicon cells of hepatitis C virus. J Virol (2003) 1.20
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2001) 1.19
Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer. J Virol (2005) 1.17
HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharmacol (2002) 1.13
Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J Virol (2002) 1.13
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther (2007) 1.13
Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.12
Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog (2012) 1.11
Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry (2002) 1.11
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2006) 1.08
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother (2007) 1.05
The amino-terminal domain of bovine viral diarrhea virus Npro protein is necessary for alpha/beta interferon antagonism. J Virol (2006) 1.03
Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics. J Virol (2011) 1.02
Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother (2003) 1.00
Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother (2005) 0.99
Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir Chem Chemother (2003) 0.99
Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother (2003) 0.98
ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. PLoS One (2012) 0.98
Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. Bioorg Med Chem Lett (2006) 0.97
Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. Antiviral Res (2003) 0.96
Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res (2009) 0.95
Involvement of a bovine viral diarrhea virus NS5B locus in virion assembly. J Virol (2004) 0.95
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother (2014) 0.94
Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother (2003) 0.93
Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Rev Med Chem (2005) 0.93
Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem (2013) 0.93
The Arabidopsis homolog of the mammalian OS-9 protein plays a key role in the endoplasmic reticulum-associated degradation of misfolded receptor-like kinases. Mol Plant (2012) 0.93
Beyond nutrients: food-derived microRNAs provide cross-kingdom regulation. Bioessays (2012) 0.92
PtdIns(4)P regulates retromer-motor interaction to facilitate dynein-cargo dissociation at the trans-Golgi network. Nat Cell Biol (2013) 0.92
Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol (2002) 0.91
Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother (2011) 0.91
Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antivir Chem Chemother (2004) 0.91
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2006) 0.90
Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J Virol (2005) 0.90
The quality of life after bar removal in patients after the nuss procedure for pectus excavatum. World J Surg (2011) 0.90
Viability of poliovirus/rhinovirus VPg chimeric viruses and identification of an amino acid residue in the VPg gene critical for viral RNA replication. J Virol (2003) 0.89
Design, synthesis, and antiviral activity of adenosine 5'-phosphonate analogues as chain terminators against hepatitis C virus. J Med Chem (2005) 0.89
Endoscopic evaluation of the quality of the anastomosis after esophagectomy with gastric tube reconstruction. World J Surg (2008) 0.89
Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett (2005) 0.89
Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett (2007) 0.87
Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett (2007) 0.87
Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother (2004) 0.87
Effects of heat shock protein gp96 on human dendritic cell maturation and CTL expansion. Biochem Biophys Res Commun (2006) 0.86
Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother (2005) 0.86
SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Antiviral Res (2012) 0.85
Promising candidates for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2003) 0.84
Modified Ravitch procedure: using a pectus bar for posttraumatic pectus excavatum. Ann Thorac Surg (2007) 0.84
Narrow bandpass tunable terahertz filter based on photonic crystal cavity. Appl Opt (2012) 0.83
Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem (2013) 0.83
Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells. Antimicrob Agents Chemother (2011) 0.82
Substituted imidazopyridines as potent inhibitors of HCV replication. J Hepatol (2009) 0.82
Hepatitis C virus NS5A hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment. J Virol (2014) 0.82
Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg Med Chem Lett (2006) 0.82
Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs (2003) 0.82
Terahertz gas sensing based on a simple one-dimensional photonic crystal cavity with high-quality factors. Appl Opt (2014) 0.81
Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob Agents Chemother (2002) 0.81
Synthesis of 2'-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors. Bioorg Med Chem Lett (2005) 0.81
Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model. J Clin Immunol (2012) 0.80
Identification of novel, selective and potent Chk2 inhibitors. Bioorg Med Chem Lett (2006) 0.80
Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus. PLoS One (2012) 0.80
Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV. Antivir Ther (2012) 0.80
HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr Opin Investig Drugs (2006) 0.80
Development of new and selective Trypanosoma cruzi trans-sialidase inhibitors from sulfonamide chalcones and their derivatives. Chembiochem (2009) 0.80
Optimized high-throughput screen for hepatitis C virus translation inhibitors. J Biomol Screen (2011) 0.80